HIV/AIDS National Strategic Plans of Sub-Saharan African countries: an analysis for gender equality and sex-disaggregated HIV targets

Health Policy and Planning
Volume 32, Issue 10, 1 December 2017
http://heapol.oxfordjournals.org/content/current

Editor’s Choice
HIV/AIDS National Strategic Plans of Sub-Saharan African countries: an analysis for gender equality and sex-disaggregated HIV targets
Jennifer Sherwood; Alana Sharp; Bergen Cooper; Beirne Roose-Snyder; Susan Blumenthal
Health Policy and Planning, Volume 32, Issue 10, 1 December 2017, Pages 1361–1367, https://doi.org/10.1093/heapol/czx101
Abstract
National Strategic Plans (NSPs) for HIV/AIDS are country planning documents that set priorities for programmes and services, including a set of targets to quantify progress toward national and international goals. The inclusion of sex-disaggregated targets and targets to combat gender inequality is important given the high disease burden among young women and adolescent girls in Sub-Saharan Africa, yet no comprehensive gender-focused analysis of NSP targets has been performed. This analysis quantitatively evaluates national HIV targets, included in NSPs from eighteen Sub-Saharan African countries, for sex-disaggregation. Additionally, NSP targets aimed at reducing gender-based inequality in health outcomes are compiled and inductively coded to report common themes. On average, in the eighteen countries included in this analysis, 31% of NSP targets include sex-disaggregation (range 0–92%). Three countries disaggregated a majority (>50%) of their targets by sex. Sex-disaggregation in data reporting was more common for targets related to the early phases of the HIV care continuum: 83% of countries included any sex-disaggregated targets for HIV prevention, 56% for testing and linkage to care, 22% for improving antiretroviral treatment coverage, and 11% for retention in treatment. The most common target to reduce gender inequality was to prevent gender-based violence (present in 50% of countries). Other commonly incorporated target areas related to improving women’s access to family planning, human and legal rights, and decision-making power. The inclusion of sex-disaggregated targets in national planning is vital to ensure that programmes make progress for all population groups. Improving the availability and quality of indicators to measure gender inequality, as well as evaluating programme outcomes by sex, is critical to tracking this progress. This analysis reveals an urgent need to set specific and separate targets for men and women in order to achieve an equitable and effective HIV response and align government planning with international priorities for gender equality.

Humanitarian Exchange Magazine Number 70 October 2017

Humanitarian Exchange Magazine
http://odihpn.org/magazine/the-humanitarian-consequences-of-violence-in-central-america/
Number 70   October 2017
Special Feature: The Lake Chad Basin: an overlooked crisis?
by Humanitarian Practice Network October 2017
The 70th edition of Humanitarian Exchange, co-edited with Joe Read, focuses on the humanitarian crisis in Nigeria and the Lake Chad Basin. The violence perpetrated by Boko Haram and the counter-insurgency campaign in Nigeria, Cameroon, Chad and Niger has created a humanitarian crisis affecting some 17 million people. Some 2.4 million have been displaced, the vast majority of them in north-eastern Nigeria. Many are living in desperate conditions, without access to sufficient food or clean water. The Nigerian government’s focus on defeating Boko Haram militarily, its reluctance to acknowledge the scale and gravity of the humanitarian crisis and the corresponding reticence of humanitarian leaders to challenge that position have combined to undermine the timeliness and effectiveness of the response…

[Reviewed earlier]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines) Volume 13, Issue 11 2017

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 13, Issue 11 2017
http://www.tandfonline.com/toc/khvi20/current

Article
Effect of combination vaccines on completion and compliance of childhood vaccinations in the United States
Samantha K. Kurosky, Keith L. Davis & Girishanthy Krishnarajah
Pages: 2494-2502
Published online: 07 Sep 2017

Review
Interventions to increase pediatric vaccine uptake: An overview of recent findings
Paula M. Frew & Chelsea S. Lutz
Pages: 2503-2511
Published online: 26 Sep 2017

Article
Effectiveness of a smartphone app to increase parents’ knowledge and empowerment in the MMR vaccination decision: A randomized controlled trial
Marta Fadda, Elisa Galimberti, Maddalena Fiordelli, Luisa Romanò, Alessandro Zanetti & Peter J. Schulz
Pages: 2512-2521
Published online: 10 Nov 2017

Brief Report
The 2016 Lifetime Immunization Schedule, approved by the Italian scientific societies: A new paradigm to promote vaccination at all ages
Paolo Bonanni, Giampietro Chiamenti, Giorgio Conforti, Tommasa Maio, Anna Odone, Rocco Russo, Silvestro Scotti, Carlo Signorelli, Alberto Villani & The Scientific Board of “Lifetime Immunization Schedule”
Pages: 2531-2537
Published online: 19 Oct 2017

Article
Improved parental attitudes and beliefs through stepwise perinatal vaccination education
Aya Saitoh, Akihiko Saitoh, Isamu Sato, Tomohiro Shinozaki, Hajime Kamiya & Satoko Nagata
Pages: 2639-2645
Published online: 30 Aug 2017

Article
Immunization attitudes and practices among family medicine providers
Cynthia A. Bonville, Joseph B. Domachowske, Donald A. Cibula & Manika Suryadevara
Pages: 2646-2653
Published online: 13 Oct 2017

Article
Vaccination among Polish university students. Knowledge, beliefs and anti-vaccination attitudes
Michał Konrad Zarobkiewicz, Aleksandra Zimecka, Tomasz Zuzak, Dominika Cieślak, Jacek Roliński & Ewelina Grywalska
Pages: 2654-2658
Published online: 21 Sep 2017

Article
Approaching a decade since HPV vaccine licensure: Racial and gender disparities in knowledge and awareness of HPV and HPV vaccine
Eric Adjei Boakye, Betelihem B. Tobo, Rebecca P. Rojek, Kahee A. Mohammed, Christian J. Geneus & Nosayaba Osazuwa-Peters
Pages: 2713-2722
Published online: 30 Aug 2017

Article commentary
Human papilloma virus vaccine for low and middle income countries: A step too soon?
Har Ashish Jindal, Amanjot Kaur & Sathiabalan Murugan
Pages: 2723-2725
Published online: 28 Aug 2017

An ageing world of the 21st century: a literature review

International Journal of Community Medicine and Public Health
Vol 4, No 12 (2017)  December 2017
http://www.ijcmph.com/index.php/ijcmph/issue/view/33

Review Articles
An ageing world of the 21st century: a literature review
Sarah Naja, Mohamed Mohei El Din Makhlouf, Mohamad Abdul Halim Chehab
DOI: 10.18203/2394-6040.ijcmph20175306
Abstract
Aging is the process of growing older at cellular, organ, or whole body level throughout the life span. Furthermore, the term “demographic transition” refers to a shift in fertility and mortality rates leading to changes in population growth rates, and age distribution. Thus, as people globally live longer, increasing levels of chronic illness as well as diminished wellbeing are nominated to become major global health challenges. Subsequently, the global population of elderly is projected to further increase and reach 1.4 billion by 2030 and 2.1 billion by 2050. Moreover, ageing has important implications on social security, the economy, the organization and delivery of health care, caregiver availability and constraints, society, and policies. Thus, it is pertinent to establish comprehensive elderly-friendly health care with further focus on preventive action to maintain a healthy ageing process.

 

The Revised Declaration of GenevaA Modern-Day Physician’s Pledge

JAMA
November 28, 2017, Vol 318, No. 20, Pages 1955-2054
http://jama.jamanetwork.com/issue.aspx

Viewpoint
The Revised Declaration of GenevaA Modern-Day Physician’s Pledge
Ramin Walter Parsa-Parsi, MD, MPH
free access
JAMA. 2017;318(20):1971-1972. doi:10.1001/jama.2017.16230
This Viewpoint describes the 2017 revision of the World Medical Association’s Declaration of Geneva, which asks physicians to pledge themselves to the highest standards of ethics and practice in the interests of their patients and the medical profession.

Reporting from 8th International Congress on Peer Review and Scientific Publication: Challenges and opportunities for China’s periodical and press industries (pages 243–244)

Journal of Evidence-Based Medicine
November 2017  Volume 10, Issue 4  Pages 241–333
http://onlinelibrary.wiley.com/doi/10.1111/jebm.2017.10.issue-4/issuetoc

EDITORIAL
Reporting from 8th International Congress on Peer Review and Scientific Publication: Challenges and opportunities for China’s periodical and press industries (pages 243–244)
Yonggang Zhang, Liang Du and Youping Li
Version of Record online: 29 NOV 2017 | DOI: 10.1111/jebm.12279

Essential medicines lists for children of WHO, India, South Africa, and EML of China: A comparative study (pages 271–280)

Journal of Evidence-Based Medicine
November 2017  Volume 10, Issue 4  Pages 241–333
http://onlinelibrary.wiley.com/doi/10.1111/jebm.2017.10.issue-4/issuetoc
EDITORIAL

Articles
Essential medicines lists for children of WHO, India, South Africa, and EML of China: A comparative study (pages 271–280)
Dan Liu, Jing Cheng, Ling-Li Zhang, You-Ping Li, Li-Nan Zeng, Chuan Zhang and Ge Gui
Version of Record online: 24 MAY 2017 | DOI: 10.1111/jebm.12240
Abstract
Objective
Comparing the essential medicine lists for children and China national essential medicine list 2012, to provide the evidence for establishing essential medicine list for children in China.
Methods
Search the official websites of WHO and some other countries’ ministry of health to get essential medicine lists for children (EMLc) that have already established. Compare the situation of updating, the number and classification of medicines, and the dosage forms in essential medicine lists for children and China national essential medicine list 2012.
Results
By December 2013, the WHO, India, and South Africa have established EMLc. The list of China was for people in all ages, so the number of medicines ranked first in four lists. WHO, India, and China classified the medicines by pharmacologic action, South Africa classified by ATC classification. Except for WHO, India, South Africa, and China did not have specific medicines for neonatal care or medicines for diseases of joints. The main administration routes in these four lists were oral administration, injection, and topical application. There were medicine restrictions in lists of WHO and India, but there were no medicine restrictions in the lists of South Africa and China.
Conclusion
Compared with EMLs for children, the 2012 National Essential Medicine List for China is not suitable for children in China. Development of Chinese EMLc should be based on the burden of diseases for children, and should select applicable dosage forms and specifications.

Typhoid vaccine development with a human challenge model

The Lancet
Dec 02, 2017 Volume 390 Number 10111 p2413-2526  e43-e49
http://www.thelancet.com/journals/lancet/issue/current

Comment
Typhoid vaccine development with a human challenge model
Nicholas A Feasey, Myron M Levine
Published: 2 December 2017
Experimental human typhoid fever challenge was first described in 1896 by Wright, who vaccinated two men against typhoid fever and challenged one with what was then known as Salmonella typhosa.1 While challenge models are sometimes controversial, they offer enormous potential to study the pathogenesis of disease and to accelerate vaccine development, particularly in human-restricted pathogens such as Salmonella enterica serovar Typhi. The Maryland typhoid human challenge model, which ran from 1952 to 1974, led to insights into typhoid fever and facilitated the development of live attenuated typhoid vaccine Ty21a.2, 3 A 21st-century typhoid challenge model has been developed by the Oxford Vaccine Group.4

In The Lancet, Celina Jin and colleagues5 report results from challenging three groups of healthy adults from Oxford, UK, who were randomly assigned to receive Vi-conjugate vaccine, unconjugated Vi-polysaccharide vaccine, or control vaccine (ACYW135 meningococcal conjugate) with wild-type Quailes strain Salmonella Typhi. Results of this volunteer challenge have been awaited with much anticipation by the public health community interested in control of typhoid fever in endemic areas of south Asia and sub-Saharan Africa where S Typhi is increasingly antibiotic resistant and few treatment options remain. Vi-conjugate vaccines that have been in development represent a new instrument to help to control typhoid. The most advanced conjugate vaccine, Typbar-TCV (Vi-polysaccharide [Vi-PS] conjugated to tetanus toxoid, Vi-TT, Bharat Biotech, Hyderabad, India), is licensed in India where it has been shown to elicit robust serum Vi antibody responses after only one dose, even in Indian infants as young as 6 months.6 In toddlers, older children, and adults, Typbar-TCV was shown to be significantly more immunogenic than the unconjugated Bharat Vi-PS.6 Bharat Biotech has submitted an application to WHO for pre-qualification of their Vi-TT. If approved, this would allow the vaccine to be procured by UN agencies. However, despite evidence of safety and immunogenicity in Indian children and adults, heretofore, there has been no evidence of actual efficacy of the vaccine in diminishing the attack rate of typhoid fever upon exposure to virulent S Typhi compared with the control participants. Importantly, the authors provide the first data documenting that Typbar-TCV is protective.

112 participants were enrolled in this observer and participant-blinded, randomised controlled trial, which showed that the Vi-TT is well tolerated, achieved 100% seroconversion of Vi antibody (versus 89% for Vi-PS), and stimulated significantly higher geometric mean titres than did unconjugated Vi-PS. Most importantly, Jin and colleagues document that Vi-TT recipients had a significantly lower attack rate for the primary aim endpoint diagnosing typhoid fever than control recipients. With the primary endpoint used in this ambitious trial, the attack rate for typhoid diagnosis was 24 (77%) of 31 in control participants, 13 (35%) of 37 in Vi-TT recipients, and 13 (35%) of 35 in those who received Vi-PS. This translates into vaccine efficacies of 54·6% (95% CI 26·8–71·8) for Vi-TT and 52·0% (23·2–70·0) for Vi-PS.

As the authors suggest, the field efficacy of Vi-TT vaccine might be higher; for example, a well designed and executed field trial of an unlicensed Vi-conjugate produced by the National Institutes of Health (Bethesda, MD, USA) in Vietnamese pre-school children showed an efficacy of 89% (95% CI 76–97) over 46 months of follow-up.7 One possible explanation lies in the primary endpoint of so-called typhoid infection used by Jin and colleagues5 (persistent fever ≥38°C for ≥12 h or S Typhi bacteraemia), which arguably is better suited to studying typhoid pathogenesis than assessing the efficacy of typhoid vaccines. Using slightly different endpoints such as fever 38°C or higher followed by a positive blood culture, similar to surveillance in a field trial and to endpoints used in the Maryland challenge model, Jin and colleagues5 report that the efficacy of Vi-TT was 87·1% (95% CI 47·2–96·9), while efficacy of Vi-PS was 52·3% (−4·2 to 78·2). Although future typhoid challenges based on this as a co-primary endpoint would require larger sample sizes, the information gained might be more relevant and predictive of the efficacy that might be noted in a randomised controlled field trial. This highlights the need for the phase 3 and 4 trials, the first of which is expected to be initiated in Asia in late 2017 by the Typhoid Vaccine Acceleration Consortium (TyVAC), a partnership between the University of Maryland, the University of Oxford, and PATH funded by the Bill & Melinda Gates Foundation. However, because it will be some years before these field trials are reported, Jin and colleagues’ challenge study results are timely and engender optimism that an effective new instrument has become available to help to control typhoid in hyperendemic populations.
NAF declares no competing interests. MML reports co-developing, with colleagues, a Salmonella Enteritidis/Salmonella Typhimurium/Salmonella Typhi Vi trivalent conjugate vaccine against invasive Salmonella disease in sub-Saharan Africa with Bharat Biotech International as a partner and funding from a Strategic Translation Award from the Wellcome Trust. MML has a US patent, 9011871, issued April 21, 2016, for Broad Spectrum Vaccine Against Typhoidal and non-typhoidal Salmonella disease, for which MML along with James E Galen, Raphael Simon, and Sharon Tennant are inventors.

Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial

The Lancet
Dec 02, 2017 Volume 390 Number 10111 p2413-2526  e43-e49
http://www.thelancet.com/journals/lancet/issue/current

Articles
Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial
Celina Jin, Malick M Gibani, Maria Moore, Helene B Juel, Elizabeth Jones, James Meiring, Victoria Harris, Jonathan Gardner, Anna Nebykova, Simon A Kerridge, Jennifer Hill, Helena Thomaides-Brears, Christoph J Blohmke, Ly-Mee Yu, Brian Angus, Andrew J Pollard
2472
Open Access
Summary
Background
Salmonella enterica serovar Typhi (S Typhi) is responsible for an estimated 20 million infections and 200 000 deaths each year in resource poor regions of the world. Capsular Vi-polysaccharide-protein conjugate vaccines (Vi-conjugate vaccines) are immunogenic and can be used from infancy but there are no efficacy data for the leading candidate vaccine being considered for widespread use. To address this knowledge gap, we assessed the efficacy of a Vi-tetanus toxoid conjugate vaccine using an established human infection model of S Typhi.
Methods
In this single-centre, randomised controlled, phase 2b study, using an established outpatient-based human typhoid infection model, we recruited healthy adult volunteers aged between 18 and 60 years, with no previous history of typhoid vaccination, infection, or prolonged residency in a typhoid-endemic region. Participants were randomly assigned (1:1:1) to receive a single dose of Vi-conjugate (Vi-TT), Vi-polysaccharide (Vi-PS), or control meningococcal vaccine with a computer-generated randomisation schedule (block size 6). Investigators and participants were masked to treatment allocation, and an unmasked team of nurses administered the vaccines. Following oral ingestion of S Typhi, participants were assessed with daily blood culture over a 2-week period and diagnosed with typhoid infection when meeting pre-defined criteria. The primary endpoint was the proportion of participants diagnosed with typhoid infection (ie, attack rate), defined as persistent fever of 38°C or higher for 12 h or longer or S Typhi bacteraemia, following oral challenge administered 1 month after Vi-vaccination (Vi-TT or Vi-PS) compared with control vaccination. Analysis was per protocol. This trial is registered with ClinicalTrials.gov, number NCT02324751, and is ongoing.
Findings
Between Aug 18, 2015, and Nov 4, 2016, 112 participants were enrolled and randomly assigned; 34 to the control group, 37 to the Vi-PS group, and 41 to the Vi-TT group. 103 participants completed challenge (31 in the control group, 35 in the Vi-PS group, and 37 in the Vi-TT group) and were included in the per-protocol population. The composite criteria for typhoid diagnosis was met in 24 (77%) of 31 participants in the control group, 13 (35%) of 37 participants in the Vi-TT group, and 13 (35%) of 35 participants in the Vi-PS group to give vaccine efficacies of 54·6% (95% CI 26·8–71·8) for Vi-TT and 52·0% (23·2–70·0) for Vi-PS. Seroconversion was 100% in Vi-TT and 88·6% in Vi-PS participants, with significantly higher geometric mean titres detected 1-month post-vaccination in Vi-TT vaccinees. Four serious adverse events were reported during the conduct of the study, none of which were related to vaccination (one in the Vi-TT group and three in the Vi-PS group).
Interpretation
Vi-TT is a highly immunogenic vaccine that significantly reduces typhoid fever cases when assessed using a stringent controlled model of typhoid infection. Vi-TT use has the potential to reduce both the burden of typhoid fever and associated health inequality.
Funding
The Bill & Melinda Gates Foundation and the European Commission FP7 grant, Advanced Immunization Technologies (ADITEC).

Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review

Lancet Global Health
Dec 2017 Volume 5 Number 12 e1161-e1282
http://www.thelancet.com/journals/langlo/issue/current

Articles
Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review
Sarah Larney, Amy Peacock, Janni Leung, Samantha Colledge, Matthew Hickman, Peter Vickerman, Jason Grebely, Kostyantyn V Dumchev, Paul Griffiths, Lindsey Hines, Evan B Cunningham, Richard P Mattick, Michael Lynskey, John Marsden, John Strang, Louisa Degenhardt
e1208

An effective and safe vaccine will not be enough to prepare us for the next Ebola outbreak

Lancet Infectious Diseases
Dec 2017 Volume 17 Number 12 p1219-1318  e383-e433
http://www.thelancet.com/journals/laninf/issue/current

Comment
An effective and safe vaccine will not be enough to prepare us for the next Ebola outbreak
John S Schieffelin
Open Access – Excerpt
…Although this study [Gsell et al] is noteworthy because it provides substantially more safety and efficacy data for the rVSV-EBOV vaccine, it also points out two major hurdles remaining that every Ebola vaccine must overcome in the future, and for the cautionary tale that it provides, one that the international community will hopefully heed. First, the reported adverse event rate in Ebola ça Suffit! was 53·9%, with 98·5% classified as mild to moderate.5 In the present study, the vaccine was better tolerated with only 16% of children and 34% of adults reporting adverse events. With an adverse event rate of up to 50%, social mobilisation efforts to encourage vaccination participation will be challenging in future Ebola outbreaks. How many people refuse the seasonal influenza vaccine each year because they think it gives them the flu? Now imagine a scenario in which people think the vaccine could give them Ebola. This issue leads directly to the vaccine’s second hurdle: misconceptions, rumours, and community resistance. 34% of eligible contacts in Ebola Ça Suffit! refused or withdrew consent.5 In the current study, one affected community refused participation due to mistrust of the Ebola surveillance teams. Community resistance played a prominent part in the spread of Ebola virus during the 2013–15 outbreak.6 A weak public health infrastructure and widespread shortages of health-care workers contributed to fears and misconceptions about an unfamiliar disease with a high mortality. One that is treated in walled-off Ebola treatment units and requires medical burials, denying family members the solace provided by traditional funeral rites. These conditions fuelled rumours, mistrust, and, in some cases, violence. Surveillance, social mobilisation, and vaccination teams trained in distant capitals must seek input and support from local leaders or they risk developing a sense of coercion and distrust…7, 8

Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report

Lancet Infectious Diseases
Dec 2017 Volume 17 Number 12 p1219-1318  e383-e433
http://www.thelancet.com/journals/laninf/issue/current

Articles

Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report
Pierre-Stéphane Gsell, Anton Camacho, Adam J Kucharski, Conall H Watson, Aminata Bagayoko, Séverine Danmadji Nadlaou, Natalie E Dean, Abdourahamane Diallo, Abdourahmane Diallo, Djidonou A Honora, Moussa Doumbia, Godwin Enwere, Elizabeth S Higgs, Thomas Mauget, Diakite Mory, Ximena Riveros, Fofana Thierno Oumar, Mosoka Fallah, Alhassane Toure, Andrea S Vicari, Ira M Longini, W J Edmunds, Ana Maria Henao-Restrepo, Marie Paule Kieny, Sakoba Kéïta
Open Access
Summary
Background
In March, 2016, a flare-up of Ebola virus disease was reported in Guinea, and in response ring vaccination with the unlicensed rVSV-ZEBOV vaccine was introduced under expanded access, the first time that an Ebola vaccine has been used in an outbreak setting outside a clinical trial. Here we describe the safety of rVSV-ZEBOV candidate vaccine and operational feasibility of ring vaccination as a reactive strategy in a resource-limited rural setting.
Methods
Approval for expanded access and compassionate use was rapidly sought and obtained from relevant authorities. Vaccination teams and frozen vaccine were flown to the outbreak settings. Rings of contacts and contacts of contacts were defined and eligible individuals, who had given informed consent, were vaccinated and followed up for 21 days under good clinical practice conditions.
Findings
Between March 17 and April 21, 2016, 1510 individuals were vaccinated in four rings in Guinea, including 303 individuals aged between 6 years and 17 years and 307 front-line workers. It took 10 days to vaccinate the first participant following the confirmation of the first case of Ebola virus disease. No secondary cases of Ebola virus disease occurred among the vaccinees. Adverse events following vaccination were reported in 47 (17%) 6–17 year olds (all mild) and 412 (36%) adults (individuals older than 18 years; 98% were mild). Children reported fewer arthralgia events than adults (one [<1%] of 303 children vs 81 [7%] of 1207 adults). No severe vaccine-related adverse events were reported.
Interpretation
The results show that a ring vaccination strategy can be rapidly and safely implemented at scale in response to Ebola virus disease outbreaks in rural settings.
Funding
WHO, Gavi, and the World Food Programme.

Lancet Infectious Diseases Dec 2017 Volume 17 Number 12 p1219-1318 e383-e433

Lancet Infectious Diseases
Dec 2017 Volume 17 Number 12 p1219-1318  e383-e433
http://www.thelancet.com/journals/laninf/issue/current

Articles
Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study
Kimberley Kavanagh, Kevin G Pollock, Kate Cuschieri, Tim Palmer, Ross L Cameron, Cameron Watt, Ramya Bhatia, Catherine Moore, Heather Cubie, Margaret Cruickshank, Chris Robertson

Review
The basic reproduction number (R0) of measles: a systematic review
Fiona M Guerra, Shelly Bolotin, Gillian Lim, Jane Heffernan, Shelley L Deeks, Ye Li, Natasha S Crowcroft

Influences on Immunization Decision-Making among US Parents of Young Children

Maternal and Child Health Journal
Volume 21, Issue 12, December 2017
https://link.springer.com/journal/10995/21/12/page/1

Original Paper
Influences on Immunization Decision-Making among US Parents of Young Children
This study assessed influences on vaccination decisions among parents of young children and examined common vaccination information and advice sources.
Yunmi Chung, Jay Schamel, Allison Fisher

HIV Prevention Efforts and Incidence of HIV in Uganda

New England Journal of Medicine
November 30, 2017  Vol. 377 No. 22
http://www.nejm.org/toc/nejm/medical-journal

Original Article
HIV Prevention Efforts and Incidence of HIV in Uganda
Kate Grabowski, Ph.D., David M. Serwadda, M.B., Ch.B., M.P.H., Ronald H. Gray, M.D., Gertrude Nakigozi, M.B., Ch.B., Ph.D., Godfrey Kigozi, M.B., Ch.B., Ph.D., Joseph Kagaayi, M.B., Ch.B., Ph.D., Robert Ssekubugu, M.S.P.H., Fred Nalugoda, Ph.D., Justin Lessler, Ph.D., M.H.S., Thomas Lutalo, Ph.D., Ronald M. Galiwango, M.B., Ch.B., Sc.M., Fred Makumbi, Ph.D., Xiangrong Kong, Ph.D., Donna Kabatesi, M.D., M.P.H., Stella T. Alamo, M.D., M.P.H., Steven Wiersma, M.D., M.P.H., Nelson K. Sewankambo, M.B., Ch.B., Aaron A.R. Tobian, M.D., Ph.D., Oliver Laeyendecker, Ph.D., Thomas C. Quinn, M.D., Steven J. Reynolds, M.D., M.P.H., Maria J. Wawer, M.D., and Larry W. Chang, M.D., M.P.H., for the Rakai Health Sciences Program*

N Engl J Med 2017; 377:2154-2166 November 30, 2017 DOI: 10.1056/NEJMoa1702150
To assess the effect of a combination strategy for prevention of human immunodeficiency virus (HIV) on the incidence of HIV infection, we analyzed the association between the incidence of HIV and the scale-up of antiretroviral therapy (ART) and medical male circumcision in Rakai, Uganda. Changes in population-level viral-load suppression and sexual behaviors were also examined.

Pediatrics – December 2017, VOLUME 140 / ISSUE 6

 
Pediatrics
December 2017, VOLUME 140 / ISSUE 6
http://pediatrics.aappublications.org/content/140/6?current-issue=y

Articles
Web-based Social Media Intervention to Increase Vaccine Acceptance: A Randomized Controlled Trial
Jason M. Glanz, Nicole M. Wagner, Komal J. Narwaney, Courtney R. Kraus, Jo Ann Shoup, Stanley Xu, Sean T. O’Leary, Saad B. Omer, Kathy S. Gleason, Matthew F. Daley
Pediatrics Dec 2017, 140 (6) e20171117; DOI: 10.1542/peds.2017-1117
In this RCT, we compare vaccination outcomes in infants of pregnant women exposed to either a VSM intervention, a VI Web site, or UC.

Articles
4-Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10 Years
Daron G. Ferris, Rudiwilai Samakoses, Stanley L. Block, Eduardo Lazcano-Ponce, Jaime Alberto Restrepo, Jesper Mehlsen, Archana Chatterjee, Ole-Erik Iversen, Amita Joshi, Jian-Li Chu, Andrea Likos Krick, Alfred Saah, Rituparna Das
Pediatrics Dec 2017, 140 (6) e20163947; DOI: 10.1542/peds.2016-3947
This report summarizes the immunogenicity, effectiveness, and safety of the 4vHPV vaccine in adolescent and preadolescent subjects after 10 years.

malERA: An updated research agenda for malaria elimination and eradication

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 2 December 2017)

Collection Review
malERA: An updated research agenda for malaria elimination and eradication
Regina N. Rabinovich, Chris Drakeley, Abdoulaye A. Djimde, B. Fenton Hall, Simon I. Hay, Janet Hemingway, David C. Kaslow, Abdisalan Noor, Fredros Okumu, Richard Steketee, Marcel Tanner, Timothy N. C. Wells, Maxine A. Whittaker, Elizabeth A. Winzeler, Dyann F. Wirth, Kate Whitfield, Pedro L. Alonso
| published 30 Nov 2017 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1002456
Abstract
Achieving a malaria-free world presents exciting scientific challenges as well as overwhelming health, equity, and economic benefits. WHO and countries are setting ambitious goals for reducing the burden and eliminating malaria through the “Global Technical Strategy” and 21 countries are aiming to eliminate malaria by 2020. The commitment to achieve these targets should be celebrated. However, the need for innovation to achieve these goals, sustain elimination, and free the world of malaria is greater than ever. Over 180 experts across multiple disciplines are engaged in the Malaria Eradication Research Agenda (malERA) Refresh process to address problems that need to be solved. The result is a research and development agenda to accelerate malaria elimination and, in the longer term, transform the malaria community’s ability to eradicate it globally.

malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 2 December 2017)

Collection Review
malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication
The malERA Refresh Consultative Panel on Tools for Malaria Elimination
| published 30 Nov 2017 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1002455
Abstract
Since the turn of the century, a remarkable expansion has been achieved in the range and effectiveness of products and strategies available to prevent, treat, and control malaria, including advances in diagnostics, drugs, vaccines, and vector control. These advances have once again put malaria elimination on the agenda. However, it is clear that even with the means available today, malaria control and elimination pose a formidable challenge in many settings. Thus, currently available resources must be used more effectively, and new products and approaches likely to achieve these goals must be developed. This paper considers tools (both those available and others that may be required) to achieve and maintain malaria elimination. New diagnostics are needed to direct treatment and detect transmission potential; new drugs and vaccines to overcome existing resistance and protect against clinical and severe disease, as well as block transmission and prevent relapses; and new vector control measures to overcome insecticide resistance and more powerfully interrupt transmission. It is also essential that strategies for combining new and existing approaches are developed for different settings to maximise their longevity and effectiveness in areas with continuing transmission and receptivity. For areas where local elimination has been recently achieved, understanding which measures are needed to maintain elimination is necessary to prevent rebound and the reestablishment of transmission. This becomes increasingly important as more countries move towards elimination.

 

PLoS Medicine (Accessed 2 December 2017)

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 2 December 2017)

Collection Review
 malERA: An updated research agenda for health systems and policy research in malaria elimination and eradication
The malERA Refresh Consultative Panel on Health Systems and Policy Research
| published 30 Nov 2017 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1002454

Collection Review
malERA: An updated research agenda for combination interventions and modelling in malaria elimination and eradication
The malERA Refresh Consultative Panel on Combination Interventions and Modelling
Collection Review | published 30 Nov 2017 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1002453

Collection Review
malERA: An updated research agenda for characterising the reservoir and measuring transmission in malaria elimination and eradication
The malERA Refresh Consultative Panel on Characterising the Reservoir and Measuring Transmission
Collection Review | published 30 Nov 2017 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1002452

Collection Review
malERA: An updated research agenda for basic science and enabling technologies in malaria elimination and eradication
The malERA Refresh Consultative Panel on Basic Science and Enabling Technologies
Collection Review | published 30 Nov 2017 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1002451

Collection Review
malERA: An updated research agenda for insecticide and drug resistance in malaria elimination and eradication
The malERA Refresh Consultative Panel on Insecticide and Drug Resistance
Collection Review | published 30 Nov 2017 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1002450

The importance of thinking beyond the water-supply in cholera epidemics: A historical urban case-study

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 2 December 2017)

Research Article
The importance of thinking beyond the water-supply in cholera epidemics: A historical urban case-study
Matthew D. Phelps, Andrew S. Azman, Joseph A. Lewnard, Marina Antillón, Lone Simonsen, Viggo Andreasen, Peter K. M. Jensen, Virginia E. Pitzer
| published 27 Nov 2017 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0006103
Conclusions/Significance
Spatially targeted cholera interventions, such as reactive vaccination or sanitation/hygiene campaigns in hotspot neighborhoods, would likely have been more effective in this epidemic than control measures aimed at interrupting long-cycle transmission, such as improving municipal water quality. We recommend public health planners consider programs aimed at interrupting short-cycle transmission as essential tools in the cholera control arsenal.

PLoS One

PLoS One
http://www.plosone.org/

Research Article
Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse
D. Raleigh, S. J. Peterson, M. Laudenbach, F. Baruffaldi, F. I. Carroll, S. D. Comer, H. A. Navarro, T. L. Langston, S. P. Runyon, S. Winston, M. Pravetoni, P. R. Pentel
| published 01 Dec 2017 PLOS ONE
https://doi.org/10.1371/journal.pone.0184876

Cost-effectiveness of expanding childhood routine immunization against Neisseria meningitidis serogroups C, W and Y with a quadrivalent conjugate vaccine in the African meningitis belt
Andreas Kuznik, Garba Iliyasu, Mohammed Lamorde, Mustapha Mahmud, Baba M. Musa, Ibrahim Nashabaru, Stephen Obaro, Idris Mohammed, Abdulrazaq G. Habib
Research Article | published 30 Nov 2017 PLOS ONE
https://doi.org/10.1371/journal.pone.0188595

Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico
Ana Patricia Ortiz, Karen J. Ortiz-Ortiz, Moraima Ríos, José Laborde, Amit Kulkarni, Matthew Pillsbury, Andreas Lauschke, Homero A. Monsanto, Cecile Marques-Goyco
Research Article | published 30 Nov 2017 PLOS ONE
https://doi.org/10.1371/journal.pone.0184540

Predictors of seasonal influenza vaccination among older adults in Thailand
Prabda Praphasiri, Darunee Ditsungnoen, Supakit Sirilak, Jarawee Rattanayot, Peera Areerat, Fatimah S. Dawood, Kim A. Lindblade
Research Article | published 29 Nov 2017 PLOS ONE
https://doi.org/10.1371/journal.pone.0188422

Moving forward on strengthening and sustaining National Immunization Technical Advisory Groups (NITAGs) globally: Recommendations from the 2nd global NITAG network meeting

Vaccine
Volume 35, Issue 50
http://www.sciencedirect.com/journal/vaccine/vol/35/issue/50

Conference report
Moving forward on strengthening and sustaining National Immunization Technical Advisory Groups (NITAGs) globally: Recommendations from the 2nd global NITAG network meeting
Open access
Pages 6925–6930
Noni E. MacDonald, Philippe Duclos, Ole Wichmann, Louise Henaff, … Rupa Rajbhandari Singh
Abstract
National Immunization Technical Advisory Groups (NITAGs) provide independent, evidence-informed advice to assist their governments in immunization policy formation. This is complex work and many NITAGs face challenges in fulfilling their roles. Inter-country NITAG collaboration opportunities have the potential to enhance NITAG function and grow the quality of recommendations. Hence the many requests for formation of a network linking NITAGs together so they can learn from each other. The first Global NITAG Network (GNN) meeting, held in 2016, led to a push to launch the GNN and grow the network. At the second GNN meeting, held June 28–29, 2017 in Berlin, the GNN was formally inaugurated. Participants discussed GNN governance, reflected on the April 2017 Strategic Advisory Group of Experts (SAGE) on Immunization conclusions concerning strengthening of NITAGs and also shared NITAG experiences in evaluation and inter-country collaborations and independence. They also discussed the role of Regional Technical Advisory Groups on Immunization (RTAGs) and regional networks. A number of issues were raised including NITAGs and communications, dissemination of recommendations and vaccine implementation as well as implications of off-label recommendations. Participants were alerted to immunization evidence assessment sites and value of sharing of resources. They also discussed potential GNN funding opportunities, developed an action plan for 2017–18 and selected a Steering Committee to help move the GNN forward. All participants agreed on the importance of the GNN and the value in attracting more countries to join the GNN.

Vaccine – Volume 35, Issue 50

Vaccine
Volume 35, Issue 50
http://www.sciencedirect.com/journal/vaccine/vol/35/issue/50

Commentary
A behavioral economics approach to the failed HPV vaccination program in Japan
Open access
Pages 6931–6933
Asami Yagi, Yutaka Ueda, Tadashi Kimura

Short communications
Driving immunization through the Medicare Annual Wellness Visit: A growing opportunity

Pages 6938–6940
Angela K. Shen, Rob Warnock, Jeffrey A. Kelman
This study analyzes Medicare Part B fee-for-service claims from 2011 to 2016 to assess AWV and seasonal influenza and pneumococcal conjugate vaccinations utilization over time.
Original research article
Dengue vaccine supplies under endemic and epidemic conditions in three dengue-endemic countries: Colombia, Thailand, and Vietnam
Pages 6957–6966
Jung-Seok Lee, Jacqueline K. Lim, Duc Anh Dang, Thi Hien Anh Nguyen, Andrew Farlow

Media/Policy Watch

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.
We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.
 
 
The Guardian
http://www.guardiannews.com/
Accessed 2 December 2017
Japanese Doctor wins 2017 John Maddox prize for countering HPV vaccine misinformation
30 November 2017
A Japanese doctor who has stood up to a campaign of misinformation around a common anti-cancer vaccine has won a prestigious prize for championing evidence in the face of hostility and personal threats.
Riko Muranaka at Kyoto University was awarded the 2017 John Maddox prize on Thursday for her efforts to explain the safety of the human papilloma virus (HPV) vaccine amid strong opposition from anti-vaccine activists and a small group of academics.
Muranaka was praised by colleagues for her courage and leadership as she endured insults, litigation and attempts to undermine her professional status as the HPV vaccine came under attack in Japan. While the jab is used without fuss in many countries, in Japan and some other nations, fears raised by campaigners have hit vaccine uptake rates…

New Yorker
http://www.newyorker.com/
Accessed 2 December 2017
Lake Chad: The World’s Most Complex Humanitarian Disaster
A Reporter at Large  By Ben Taub
December 4, 2017 Issue
Boko Haram, climate change, predatory armies, and extreme hunger are converging on a marginalized population in Central Africa.
 
New York Times
http://www.nytimes.com/
Accessed 2 December 2017
Ravaged by Cholera, Yemen Faces 2nd Preventable Scourge: Diphtheria
Aid officials said the Saudi blockade of Yemen was now impeding their ability to fight diphtheria, once thought to have been largely eradicated.
December 01, 2017 – By RICK GLADSTONE – World – Print Headline: “Diphtheria Threatens To Escalate In Yemen”

Philippines Suspends Dengue Shots After Drug Firm’s Warning
More than 740,000 students have already received Dengvaxia vaccinations, which could pose health risks for people not previously infected.
December 01, 2017 – By FELIPE VILLAMOR
[See Milestones/Perspectives above for additional details]
 
Wall Street Journal
http://online.wsj.com/home-page?_wsjregion=na,us&_homepage=/home/us
Accessed 2 December 2017
World
In Rwanda, Drones Deliver Medical Supplies to Remote Areas
By Robert Lee Hotz
Dec. 1, 2017 5:48 am ET
Several drone companies are using cutting-edge technology to deliver essential medical supplies to remote areas—and, in the process, gaining experience that could be used for shipments in more densely populated places.

Think Tanks et al

Think Tanks et al

Center for Global Development  
http://www.cgdev.org/page/press-center
Accessed 2 December 2017
Blog Post
New Evidence on the Health Loss but not the Health Gain from WHO’s 2009 AIDS Treatment Guidelines
12/1/17
Mead Over
We here at CGD tend to be critical of international agencies like WHO or the UNDP for establishing targets or guidelines without sufficient consideration of the impacts, for good and ill, of those guidelines in the affected countries. Such guidelines often apply standards more appropriate to rich countries and then pressure poor countries to behave as if they were rich.

Vaccines and Global Health: The Week in Review 25 November 2017

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

 pdf version A pdf of the current issue is available here: Vaccines and Global Health_The Week in Review_25 Nov 2017

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

Milestones :: Perspectives

Milestones :: Perspectives
 
Editor’s Note
We generally reserve this section of our digest for major strategic announcements and significant milestones in the vaccines/immunization space. We share below the text from a retirement laudation plaque that represents, in our view, such a milestone.

******

In Recognition of Exemplary Leadership in Advancing Immunization Globally,
We Hereby Honor
 
       Dr. Jean M-Marie Okwo-Bele
       Director of Immunization, Vaccines and Biologicals
       World Health Organization
       2004-2017
 
We thank you for your passion, unconditional commitment, and enduring dedicated service to public health.</em
 
Your legacy will live on in the many lives you have touched.
 
Your Friends, Colleagues and Partners Worldwide
November 2017
 
******
 
We understand that Okwo received this laudation during a celebratory event at the close of the SAGE meeting in October. Okwo’s retirement commences following his last day official working day at WHO on 29 November 2017.

We wish him a splendid next adventure…

::::::
::::::
 
IVI   [to 25 November 2017]
http://www.ivi.int/
Commemorating our 20th anniversary, IVI thanks donors, partners for support
IVI expresses our deepest gratitude to all the donors and supporters for your commitment and generosity to the Institute over the past 20 years. In particular, we wish to thank our donors and partners who joined us at our 20th Anniversary Forum held on November 15.
The Forum brought together 170 scientists, partners and friends of IVI from across Korea and around the world, including Dr. Park Neung-hoo, Minister of Health and Welfare of Korea. Present at the Celebration and Dinner were some 120 donors and supporters, including awardees of plaques who were honored for their outstanding commitment and contribution to IVI. As we move into IVI’s third decade, we look forward to the continuing friendship and partnership with our donors and partners to make an even bigger impact in vaccine science and global public health in the years ahead.
We are pleased to share with you images of the commemorative events and greetings on our 20th Anniversary from donors, partners and friends of IVI below.
   Press release: http://www.ivi.int/?mod=document&uid=954&page_id=12463
Photo images of the 20th Anniversary Forum and Celebrations:
https://www.flickr.com/photos/internationalvaccineinstitute/albums/72157666609937919

Emergencies

Emergencies
 
POLIO
Public Health Emergency of International Concern (PHEIC)
Polio this week as of 22 November 2017 [GPEI]
:: On the 14 November, the 15th IHR Emergency Committee convened to review the risk of international spread of poliovirus. The committee agreed that the risk of international spread of poliovirus remains a Public Health Emergency of International Concern (PHEIC), and recommended the extension of revised Temporary Recommendations for a further three months.
:: To mark World Children’s Day, we reported on how the polio eradication programme helps deliver a bright future to children in Nigeria.

:: Summary of newly-reported viruses this week:
Afghanistan: Four new wild poliovirus type 1 (WPV1) positive environmental samples, three collected from Kandahar province, and one from Kabul province.
Pakistan: One new WPV1 positive environmental sample, collected from Sindh province.
Syria: Seven new circulating vaccine derived poliovirus type 2 (cVDPV2) cases reported, all from Deir Ez-Zor governorate.

::::::
 
Statement of the 15th IHR Emergency Committee regarding the international spread of poliovirus
WHO statement
14 November 2017
[Excerpts; Editor’s text bolding]
The fifteenth meeting of the Emergency Committee under the International Health Regulations (2005) (IHR) regarding the international spread of poliovirus was convened by the Director-General on 14 November 2017 at WHO headquarters with members, advisers and invited member states attending via teleconference.

The Emergency Committee reviewed the data on wild poliovirus (WPV1) and circulating vaccine derived polioviruses (cVDPV). The Secretariat presented a report of progress for affected IHR States Parties subject to Temporary Recommendations. The following IHR States Parties presented an update on the current situation and the implementation of the WHO Temporary Recommendations since the Committee last met on 3 August 2017: Afghanistan, the Democratic Republic of Congo (DR Congo), Nigeria, Pakistan and the Syrian Arab Republic.
Wild polio

Overall the Committee was encouraged by continued steady progress in all three WPV1 infected countries, Afghanistan, Nigeria and Pakistan and the fall in the number of cases globally, and that international spread remained limited to between Afghanistan and Pakistan only. While falling transmission in these three countries decreased the risk of international spread, the consequences of any failure to prevent spread would increasingly be a set-back to eradication and a risk to public health, as funding winds down in the coming years.

The Committee commended the high-level commitment seen in both Afghanistan and Pakistan, and the high degree of cooperation and coordination, particularly targeting the high risk mobile populations that cross the international border, such as nomadic groups, local populations straddling the border, seasonal migrant workers and their families, repatriating refugees (official and informal), and guest children (children staying with relatives across the border). Stopping transmission in these populations remains a major challenge that cannot be under-estimated, underlining the critical continuing need for cross border activities in surveillance and vaccination.

The Committee commended the achievements in Pakistan that have resulted in the number of cases falling to just five so far in 2017; achievements included the improved accessibility, improved communication to reduce missed children and better quality supplementary immunization activities (SIA). However, WPV1 transmission continues to be widespread geographically as detected by environmental surveillance and this remains a source of major concern, notwithstanding that the intensity of environmental surveillance is now higher than previously, meaning the probability of environmental detection is now higher.
The Committee was concerned by the ongoing risks to eradication posed by the number of inaccessible and missed children in Afghanistan, particularly in the southern region resulting in ten cases to date in 2017.

The Committee was impressed by the innovations that continue to be made in Nigeria to reach children in Borno, but was very concerned that although the number of inaccessible settlements has fallen, there remains a substantial population in Borno state that is totally inaccessible, including around 160,000 – 200,000 children aged under five. The Committee concluded that there is a substantial risk that polioviruses are still circulating in these inaccessible areas. Nigeria also reported on ongoing efforts to ensure vaccination at international borders (including at airports), other transit points, IDP camps and in other areas where nomadic populations existed, but the Committee felt that efforts to date were inadequate. The Committee also noted that routine immunization, particularly in high risk areas of northern Nigeria, is performing poorly and along with polio eradication has been made a national priority. Although it is over 13 months since the last detection of WPV1 in Nigeria, the recent outbreak response assessment by global polio experts concluded ongoing transmission could not be ruled out.

There was ongoing concern about the Lake Chad basin region, and for all the countries that are affected by the insurgency, with the consequent lack of services and presence of IDPs and refugees. The risk of international spread from Nigeria to the Lake Chad basin countries or further afield in sub-Saharan Africa remains high. The Committee was encouraged that the Lake Chad basin countries including, Cameroon, Chad, the Central African Republic (CAR), Niger and Nigeria continued to be committed to sub-regional coordination of immunization and surveillance activities. However, there is concern about the Lake Chad islands which are currently inaccessible and also about significant gaps in population immunity exist in some areas of these countries in border areas with Borno, and the ongoing population movement in the sub-region was a major challenge.

Vaccine derived poliovirus
The Committee commended the efforts made in some very challenging circumstances in DR Congo and the Syrian Arab Republic. These outbreaks highlighted the presence of vulnerable under-immunized populations in areas with inaccessibility, either due to conflict or geographical remoteness. Furthermore, the delay in detection of these outbreaks illustrated that serious gaps in surveillance exist in many areas of the world, often related to weak health systems or to conflict resulting in disrupted health systems.

In DRC, there has been transmission after the initial SIA’s with geographical spread outside the health zones covered, into Tanganyika, necessitating further rounds with mOPV2. Risks are compounded by poor surveillance in many areas, and widespread gaps in population immunity.

The Committee was very concerned by the size of the outbreak in the Syrian Arab Republic, and the difficulty of reaching target populations because of the conflict. As type 2 population immunity rapidly wanes, the risk of spread within the Syrian Arab Republic and beyond its borders will increase substantially, meaning urgent action is needed to stop transmission. The Committee commended countries surrounding the outbreak zone that are responding to prevent importation, particularly among Syrian refugees in Lebanon, Jordan, and Turkey. The Committee urged any country receiving Syrian refugees, particularly from Deir Ez-Zor and Raqqa, to ensure polio vaccination with IPV.

The Committee noted with concern the recent detection of a single highly diverged VDPV2 in sewage in Mogadishu in Somalia, with genetic evidence of more than three years of replication without detection.

Conclusion
The Committee unanimously agreed that the risk of international spread of poliovirus remains a Public Health Emergency of International Concern (PHEIC), and recommended the extension of revised Temporary Recommendations for a further three months. The Committee considered the following factors in reaching this conclusion:

  • The potential risk of further spread through population movement, whether for family, social or cultural reasons, or in the context of populations displaced by insecurity, returning refugees, or nomadic populations, and the need for international coordination to address these risks, particularly between Afghanistan and Pakistan, Nigeria and its Lake Chad neighbors, and countries bordering the Syrian Arab Republic.
  • The current special and extraordinary context of being closer to polio eradication than ever before in history, with the incidence of WPV1 cases in 2017 the lowest ever recorded.
  • The risk and consequent costs of failure to eradicate globally one of the world’s most serious vaccine preventable diseases. Even though global transmission of WPV1 has fallen dramatically and with it the likelihood of international spread, the consequences and impact of international spread should it occur now would be grave and a major set-back to achieving eradication.
  • The risk of global complacency developing as the numbers of polio cases continues to fall and eradication becomes a tangible reality soon.
  • The outbreak of WPV1 (and cVDPV) in Nigeria highlighting that there are high-risk areas where surveillance is compromised by inaccessibility, resulting in ongoing circulation of WPV for several years without detection. The risk of transmission in the Lake Chad sub-region appears high.
  • The serious consequences of further international spread for the increasing number of countries in which immunization systems have been weakened or disrupted by conflict and complex emergencies. Populations in these fragile states are vulnerable to outbreaks of polio. Outbreaks in fragile states are exceedingly difficult to control and threaten the completion of global polio eradication during its end stage.
  • The importance of a regional approach and strong cross­border cooperation, as much international spread of polio occurs over land borders, while also recognizing that the risk of distant international spread remains from zones with active poliovirus transmission.
  • Additionally with respect to cVDPV:

:: cVDPVs also pose a risk for international spread, which without an urgent response with appropriate measures threatens vulnerable populations as noted above;
:: The large number of cases in the Syrian outbreak within a short space of time and close to the international border with Iraq in the context of ongoing population movement because of conflict, considerably heightens the risk of international spread;
:: The ongoing circulation of cVDPV2 in DR Congo, Nigeria, Pakistan and the Syrian Arab Republic demonstrates significant gaps in population immunity at a critical time in the polio endgame;
:: The ongoing urgency to prevent type 2 cVDPVs following the globally synchronized withdrawal of the type 2 component of the oral poliovirus vaccine in April 2016, noting that population immunity to type 2 polioviruses is rapidly waning;
:: The ongoing challenges of improving routine immunization in areas affected by insecurity and other emergencies
:: The global shortage of IPV which poses an additional risk.


Additional considerations
The Committee noted that in all the infected and vulnerable countries, routine immunization was generally quite poor, if not nationally, then in sub-national pockets. The Committee strongly encourages all these countries to make further efforts to improve routine immunization, and requested international partners to support these countries in rapidly improving routine immunization coverage to underpin eradication.

The Committee also strongly encouraged countries newly infected with WPV or cVDPV to act with a great degree of urgency in responding to outbreaks as national public health emergencies, and to ensure emergency operations are used to facilitate this accelerated response…

Based on the current situation regarding WPV1 and cVDPV, and the reports made by Afghanistan, DR Congo, Nigeria, Pakistan, and the Syrian Arab Republic, the Director-General accepted the Committee’s assessment and on 20 November 2017 determined that the situation relating to poliovirus continues to constitute a PHEIC, with respect to WPV1 and cVDPV…

::::::

Syria cVDPV2 outbreak situation report 23: 21 November 2017
Situation update 21 November 2017
…Seven (7) new cases of cVDPV2 were reported this week— 4 cases from Mayadeen and 3 from Boukamal district, Deir Ez-Zor governorate. The most recent case (by date of onset) is 9 September 2017 from Mayadeen district.
…The total number of confirmed cVDPV2 cases is 70.
…Outbreak response teams are planning a third mass immunization round to reach children under 5 with mOPV2 in areas where evidence of virus transmission continues.
…A request from the Syrian Ministry of Health for up to one (1) million doses of mOPV2 and 500 000 inactivated polio vaccine doses is being processed to ensure readiness for the second phase of the outbreak response
…Subnational immunization days aiming to reach children under 5 with bOPV started this week in areas of Rural Damascus, districts of Damascus, Homs, Aleppo and accessible areas of Deir Ez-Zor city. Children aged 2-23 months will also be reached with supplementary IPV during the subnational campaign, particularly in areas with large IDP populations.
…A joint supervisory team is monitoring the IPV campaign in all areas of Damascus, with a focus on areas where there are large IDP populations from Deir Ez-Zor to ensure campaign quality.

::::::
::::::

WHO Grade 3 Emergencies  [to 25 November 2017]
The Syrian Arab Republic
:: WHO gravely concerned by deteriorating situation in eastern Ghouta, Syrian Arab Republic
22 November 2017, Damascus, Syrian Arab Republic – Seven people have been killed and 42 people injured in Damascus city and surrounding areas in recent days.
In eastern Ghouta, Rural Damascus, local health authorities report that during a 4-day period alone from 14 to 17 November, 84 people were killed, including 17 children and 6 women; and 659 people were injured, including 127 children and 87 women.
During the same period, more than 200 surgical operations were conducted in eastern Ghouta’s overwhelmed and under-resourced hospitals.
Despite escalating violence and increasing humanitarian needs, life-saving medicines, medical equipment, and surgical supplies are prevented from entering the area…

:: Polio- Situation update 21 November 2017
[See Polio above for detail]

South Sudan
:: WHO in collaboration with the Ministry of Health established water quality control to prevent water-borne diseases in South Sudan
21 November 2017 Juba — The cost of delivering safe water, sanitation and hygiene services is a public health concern in South Sudan. To ensure high quality, sustainable water quality testing, monitoring and surveillance, WHO provided mobile water quality and safety testing kits to the National Public Health Laboratory. The mobile kits are to be used to test and monitor the quality and safety of water in the country.

Yemen
:: Yemen – Cholera Response  W46 2017 [Nov 13-Npv 19]
Highlights
Cumulative figures
-The cumulative total from 27 April 2017 to 19 Nov 2017 is 945,362 suspected cholera cases and 2,211 associated deaths, (CFR 0.23%), 1049 have been confirmed by culture.
-The median age of suspected cases is (20) and the median age of death is (38)
– 59.3 % of death were severe cases at admission
– The total proportion of severe cases among the suspected cases is 18%
– The national attack rate is 343.26 per 10,000. The five governorates with the highest cumulative attack rates per 10,000 remain Amran (801), Al Mahwit (760), Al Dhale’e (641), Abyan (491) and Sana’a (459).
– Children under 5 years old represent 27.8% of total suspected cases.
– In total, 20,884 rapid diagnostic tests (RDT) have been performed which represents 22.1% coverage.
– 2,375 cultures have been performed which represents 22.6% coverage.
– The last positive culture was on 7 Nov 2017 in Al Garahi district
– Among the 305 affected districts, 43 districts in 12 governorates (Abyen, Al Baydha, Al Hudei deh, Al mahrah, Hajjah, Lahj ,Marib, Mokal l a, Sa’dah, Seyoun, Shabwah, Taizz) did not report any suspected case the last three consecutive 3 weeks.
Governorate and District level
– At governorate level, the trend from W43-W45 decrease or was stable in all governorates.
– No district is reporting a CFR higher than 1%.
Trends
– The weekly number of cases is decreasing for the 10th consecutive week.
– The weekly proportion of severe cases has significantly decreased representing now 10% of the admitted cases.
-The use of RDTs has significantly increased since week 40.
Week 46
– 14,955 suspected cases and 6 associated deaths were reported.
– 10 % are severe cases
– 924 RDTs were performed, 176 were positive
– 0 Positive culture

::::::
 
WHO Grade 2 Emergencies  [to 25 November 2017]
Myanmar
:: Weekly Situation Report 4 – 22 November 2017
Key Highlights
…As of 21 November 2017, the cumulative number of new arrivals in all sites was 622,000. …This number includes over 341,000 arrivals in Kutupalong Balukhali expansion site, 235,000 in other camps and settlements, and 46,000 arrivals in host communities.
…153,765 adolescents and children received measles vaccination
…WHO Mental Health Gap Action Training commenced
Situation Overview
Approximately 170 health care facilities are known to be operating across all camps and settlements. However, many of these facilities provide a basic level of services and referrals for additional services within camps and outside of the camps remains a challenge. Government hospital facilities are overcrowded and do not have the resources to cope with the high volumes of referral patients. Moreover, the services provided are not standardized and the quality of health care services varies considerably.
The latest EWARS data show that fevers of unexplained origin are the most commonly reported disease (29%), followed acute respiratory infections (27%) and acute watery diarrhoea (21%). In view of the low immunization coverage among the Rohingya population, strengthening vaccination programmes is a priority.
Potential outbreaks of diarrhoeal diseases including

Rohingya refugees in Bangladesh: Health Sector Bulletin No. 1
Period: 01 October – 15 November 2017
[1] Health Situation
Around 1.2 million people are estimated to be in need of health assistance. This number includes both newly arrived Rohingyas from Myanmar since 25 August, and their host communities. Based on the public health situation analysis published on 10 October 2017, WHO has graded this crisis as a level 3 emergency. the highest possible rating.

[5.4] Vaccines and Immunization
Challenges
The baseline coverage for routine immunization is low. This, combined with crowded living conditions, lack of adequate water and sanitation and reported levels of high malnutrition, represents a public health risk to both the new arrivals and the host population.
Health Sector Response
The health sector has conducted several vaccination campaigns. In the first campaign, which ended on 3 October 2017, 135 519 children under 15 years of age were vaccinated against measles and rubella, 72 334 children under 5 years of age were vaccinated against polio and 72 064 children received Vitamin A.
To mitigate the outbreak of cholera, the International Coordinating Group (ICG) on Vaccine Provision mobilized 900,000 doses of oral cholera vaccine (OCV) for a large-scale cholera vaccination campaign among recently arrived Rohingyas and their host communities. The health sector worked with the MOHFW to plan, train volunteers, fund, implement and monitor this campaign. The campaign to administer the first dose (targeting 650 000 individuals over one year of age) was successfully implemented from 10 to 18 October 2017. It reached a total of 712 797 people, 179 848 of whom were children aged from one to five years old. To help improve personal hygiene, vaccinators handed out soap to each person vaccinated.
From 4 to 9 November 2017, the health sector supported the MOHFW in implementing the second phase of a cholera and polio vaccination campaign for children. A total of 199 472 children aged between one and five years received a second dose of oral cholera vaccine for added protection (estimated target population: 180 000), and 236 696 children under five years received oral polio vaccine (estimated target population: 210 000).
In addition, the health sector continues to support the MOHFW’s efforts to strengthen routine vaccination. Approximately 100 vaccinators have been trained on the current routine Expanded Programme on Immunization (EPI) schedule, key EPI messages, the importance of maintaining the cold chain, monitoring vaccine vials, injection safety, registration, reporting and waste management. Polio, measles and tetanus immunization began on 11 November from static sites within the camps. Through these static sites, to date 719 children have been vaccinated against polio, 589 children against measles and 476 pregnant women against tetanus.
Additionally, since 1 November, 970 children (6 months – 15 years) passing through the two transit sites have been vaccinated against measles and rubella (MR) and 1038 children under five years received oral polio vaccine (bOPV).
Establishing the routine Expanded Programme on Immunization (EPI) in camps and settlements and setting up vaccination posts at entry points into Bangladesh are both key to controlling measles and other diseases. However, in response to the significant increase in measles cases, MoHFW and health sector have agreed to rapidly initiate a measles campaign targeting 360 000 children under 15 for MR vaccination. In view of the urgency of the situation, the campaign is planned to start on 18 November and microplanning has begun…

::::::

WHO AFRO – Outbreaks and Emergencies Bulletin, Week 46: 11 – 17 November 2017
The WHO Health Emergencies Programme is currently monitoring 46 events in the region. This week’s edition covers key ongoing events, including:
:: Dengue fever in Burkina Faso,
:: Plague in Madagascar,
:: Lassa fever in Nigeria,
:: Marburg virus disease in Uganda,
:: Humanitarian Crisis in Central African Republic,
:: Humanitarian Crisis in the Democratic Republic of the Congo.

::::::
::::::
 
UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises. 
Syrian Arab Republic
:: 25 Nov 2017  Urgent Call to Address Gender-based Violence in Syria [EN/AR]

Yemen 
:: 24 Nov 2017 – Yemen: Impact of the closure of seaports and airports on the humanitarian situation – Situation Update 3 | 23 November 2017
:: 24 Nov 2017 – Yemen Humanitarian Bulletin Issue 29 | 20 November 2017
 
::::::

UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.
ROHINGYA CRISIS
:: ISCG Situation Update: Rohingya Refugee Crisis, Cox’s Bazar – 23 November 2017
::::::
::::::
 
Editor’s Note:
We will cluster these recent emergencies as below and continue to monitor the WHO webpages for updates and key developments.
 
Yellow Fever  [to 25 November 2017]
http://www.who.int/csr/disease/yellowfev/en/
Disease outbreak news
Yellow fever – Brazil – 24 November 2017

WHO & Regional Offices [to 25 November 2017]

WHO & Regional Offices [to 25 November 2017]

Uganda steps up to support women subjected to violence
24 November 2017 – Violence against women is a global public health problem. In Uganda more than half of all women have experienced violence at least once in their life, most likely from an intimate partner.
In response Uganda has developed the National Action Plan on the Elimination of Gender-based Violence. To date more than 400 health workers have been trained, helping to address violence against women….
 
The paradox of migrant women care workers
21 November 2017 – Migrating in the same numbers as men, many migrant women take on personal care work in informal and home-based settings – often without social protection, labour rights, or health care.
A new WHO report shows an emerging paradox: that migrant women carers support health and social systems, while their own health care and other needs may be unfulfilled.
   WHO Report
 
::::::
 
Weekly Epidemiological Record, 24 November 2017, vol. 92, 47 (pp. 717–728)
:: Progress towards poliomyelitis eradication: Pakistan, January 2016–September 2017
:: Performance of acute flaccid paralysis (AFP) surveillance and incidence of poliomyelitis, 2017

::::::
 
WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: Experts ramp up efforts to leave no one behind  24 November 2017
Brazzaville, 24 November 2017 – With growing momentum to ensure that…
:: Call for behaviour change in antibiotic use and prescription  24 November 2017
:: Making health services a safe place for women: Uganda steps up to support women subjected to violence  24 November 2017
:: Monitoring the efficacy of antimalarial medicines in Tanzania  23 November 2017
:: Promoting Interagency Collaboration to Ensure Pharmaceutical Manufacturing Development in Ethiopia  23 November 2017
:: Political will and evidence-based action to end TB in the African Region a must – WHO Regional Director for Africa  23 November 2017
23 November 2017 – World Health Organization (WHO) Africa…
:: WHO in collaboration with the Ministry of Health established water quality control testing hub within the National Public Health Laboratory to guide water safety management and prevent water-borne diseases in South Sudan  22 November 2017
:: EU commended for renewed commitment to boost Africa’s health development Africa on course to reach health some targets by 2030  21 November 2017
:: World Antibiotics Awareness Week in Tanzania  21 November 2017
:: Tackling antibiotic resistance in Sierra Leone  20 November 2017

WHO European Region EURO
:: Leaving no one behind in eliminating violence against women 24-11-2017
:: WHO/Europe introduces sustainable health workforce toolkit at Dublin Forum 24-11-2017
:: New HEN report reveals gaps in protection of refugees and migrants from vaccine-preventable diseases 21-11-2017
:: University of Pécs designated as WHO Collaborating Centre for migration and health 21-11-2017
:: Health in focus at the UN Climate Change Conference 21-11-2017

WHO Eastern Mediterranean Region EMRO
:: WHO gravely concerned by deteriorating situation in eastern Ghouta, Syria  22 November 2017
:: Islamic Advisory Group launches training manual on polio eradication, mother and child health and immunization  22 November 2017
 

CDC/ACIP [to 25 November 2017]

CDC/ACIP [to 25 November 2017]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
Wednesday, November 15, 2017

MMWR News Synopsis for November 24, 2017
Public Health Economic Burden Associated with Two Single Measles Case Investigations — Colorado, 2016–2017
CDC Media Relations
404-639-3286
Even a single measles case is expensive and burdensome to public health agencies. Measles can be prevented by a safe and effective vaccine. Measles outbreaks in the United States occur after introduction from international travelers and can be amplified in undervaccinated communities. Effective interruption of transmission requires timely case investigation. The Tri-County Health Department in the metropolitan Denver area assessed the total economic burden of two measles case investigations. Each case exposed hundreds of people, prompting a complex and coordinated response by multiple public health agencies. Public health costs of disease investigation in the first and second case were an estimated $49,769 and $15,573, respectively. Single measles cases prompted extensive public health action and were costly and resource intensive for local public health agencies.

Progress Toward Poliomyelitis Eradication – Pakistan, January 2016-September 2017
Interruption of wild poliovirus (WPV) circulation, and therefore eradication, is within reach in Pakistan. Despite progress made during 2016, virus is still detected in the environment of high-risk areas in the country, and children continue to be missed by vaccination efforts. These factors pose a challenge to the goal of achieving zero cases. To reach this goal, Pakistan must continue heightened polio surveillance, respond aggressively to any new cases, and vaccinate all children. Pakistan is one of three countries – including Afghanistan and Nigeria –where WPV has never stopped circulating. During 2017, Pakistan made significant improvements to its polio eradication program. As a result, the number of reported polio cases decreased by 69 percent, with five WPV cases compared to 16 cases reported during the same period in 2016. Despite the decrease, the virus continues to circulate in certain areas and children continue to be missed by immunization campaigns.

::::::

Africa CDC   [to 25 November 2017]
https://au.int/en/africacdc
No new digest content identified.

::::::

China CDC    [to 25 November 2017]
http://www.chinacdc.cn/en/ne/
No new digest content identified.
 

Announcements

Announcements

European Medicines Agency  [to 25 November 2017]
http://www.ema.europa.eu/ema/
24/11/2017
New guidelines on good manufacturing practices for advanced therapies
Adaptations ensure a high level of quality for ATMPs and patient protection

European Vaccine Initiative  [to 25 November 2017]
http://www.euvaccine.eu/news-events
20 November 2017
MVVC2 study published
EDCTP funded MVVC2 study published today in Frontiers in Immunology: showing safety and immunogenicity of malaria vectored…
 
 
FDA [to 25 November 2017]
http://www.fda.gov/NewsEvents/Newsroom/PressAnnoncements/default.htm
November 21, 2017 –
FDA approves first two-drug regimen for certain patients with HIV
The U.S. Food and Drug Administration today approved Juluca, the first complete treatment regimen containing only two drugs to treat certain adults with human immunodeficiency virus type 1 (HIV-1) instead of three or more drugs included in standard HIV treatment. Juluca is a fixed-dose tablet containing two previously approved drugs (dolutegravir and rilpivirine) to treat adults with HIV-1 infections whose virus is currently suppressed on a stable regimen for at least six months, with no history of treatment failure and no known substitutions associated with resistance to the individual components of Juluca…
 
 
IAVI  [to 25 November 2017]
https://www.iavi.org/
November 21, 2017
New Findings to Help HIV Scientists Establish ‘Template’ for Potent Antibodies
Natural-infection studies in Africa and India continue to inform HIV vaccine design
New data published today in Immunity further illuminate how some human beings generate powerful, HIV-blocking antibodies. Led by scientists at the International AIDS Vaccine Initiative (IAVI) and The Scripps Research Institute (TSRI), the results offer important insight into a potential AIDS vaccine design.
“Uncovering the process by which neutralizing antibodies develop is critical to HIV vaccine design,” said Elise Landais, Senior Research Scientist with IAVI and lead author of the study. “A small fraction of people living with HIV can naturally produce exceptionally powerful and broad antibodies that could prevent HIV from infecting their immune cells, but not until several years post-infection – long after that protection can help them. But it is of enormous interest to vaccine researchers.”…
 
MSF/Médecins Sans Frontières  [to 25 November 2017]
http://www.doctorswithoutborders.org/news-stories/press/press-releases
Press release
MSF: India’s Decision to Give Pfizer Unmerited Patent on Lifesaving Pneumonia Vaccine Limits Access for Children Globally
November 20, 2017
At High Court of Delhi hearing tomorrow, Doctors Without Borders will urge India to remain the “pharmacy of the developing world” and rethink decision that solidifies Pfizer monopoly on critical pneumonia vaccine

Sabin Vaccine Institute  [to 25 November 2017]
http://www.sabin.org/updates/pressreleases
Monday, November 20, 2017
Journalists Gather for Information Session on Vaccines
BUENOS AIRES, ARGENTINA – Today, the Sabin Vaccine Institute (Sabin) convened journalists from across Latin America to contribute to their understanding of the science of vaccines…
During the three-day information session hosted by Sabin, in partnership with the Universidad I Salud and the Centro de Estudos para la Prevención y el Control de Enfermedades Transmisibles, journalists will learn from public health experts about clinical trials, vaccine safety, how to communicate the impact of immunization, and basic epidemiology and immunology of vaccines, among other topics. By bringing together public health experts and 25 journalists from 18 countries, the information session will provide Latin American journalists with a baseline understanding of vaccines, vaccine safety and related global health issues….
 

UNAIDS [to 25 November 2017]
http://www.unaids.org/en
Update
Global ministerial conference ends with adoption of the Moscow Declaration to End TB
23 November 2017
A global ministerial conference held in Moscow, Russian Federation, on 16 and 17 November that united more than 1000 participants, including 75 ministers and 114 country delegations, concluded with the adoption of the Moscow Declaration to End TB.

The Moscow Declaration to End TB is a new commitment to increase multisectoral action and enhance accountability in the global TB response towards ending tuberculosis (TB) by 2030. The declaration will also inform the first United Nations General Assembly High-Level Meeting on TB, in 2018, which will seek to advance commitments to end TB from heads of state and government.

The declaration outlines the importance of international action to address key areas to respond to TB: sustainable financing, pursuing science, research and development and the establishment of a multisectoral accountability framework.

The conference, the First World Health Organization Global Ministerial Conference on Ending Tuberculosis in the Sustainable Development Era: a Multisectoral Response, was opened by the President of the Russian Federation, Vladimir Putin. It was attended by high-level United Nations leaders, including Amina J. Mohammed, the United Nations Deputy Secretary-General, Tedros Adhanom Ghebreyesus, the World Health Organization Director-General, and Michel Sidibé, the UNAIDS Executive Director…
[See last week’s edition for more detail]

UNICEF  [to 25 November 2017]
https://www.unicef.org/media/
Geneva Palais Briefing Note: Urgent measures to improve hygiene practices underway inside Rohingya refugee camps
GENEVA, 21 November 2017 – This is a summary of what was said by Christophe Boulierac, UNICEF Spokesperson in Geneva – to whom quoted text may be attributed – at today’s press briefing at the Palais des Nations in Geneva.

Despite progress, 180 million children face bleaker prospects than their parents – UNICEF
NEW YORK, 20 November 2017 – Despite global progress, 1 in 12 children worldwide live in countries where their prospects today are worse than those of their parents, according to a UNICEF analysis conducted for World Children’s Day.

Wellcome Trust  [to 25 November 2017]
https://wellcome.ac.uk/news
November 21, 2017  STAT
First Opinion
Focused projects can help Tedros restore confidence in the WHO
By Jeremy Farrar
Like many people around the world, I was dismayed last month by the appointment of Robert Mugabe, the embattled president of Zimbabwe, as a World Health Organization goodwill ambassador. While I believe it is important for the WHO to work with political leaders of every variety, Mugabe’s record in Zimbabwe, which has led to incredible pressure for him to step down, made him profoundly unsuitable for such a role. That wasn’t the only reason this decision seemed so extraordinary to me: It stands as an outlier amid many very sound judgments made by Tedros Adhanom Ghebreyesus, WHO’s newly elected director-general.

In his first 100 days in office, Tedros, as he is known, has assembled an able and extremely diverse senior leadership team. He has also engaged meaningfully and constructively with critics — not least by quickly reversing the Mugabe appointment and without equivocation. He acknowledged a misstep and, I believe, deserves our support because his leadership is a critical opportunity to rebuild the WHO into the force it should be in global health.

Tedros’s election has given him a mandate that no other head of a United Nations agency can claim. His election was the first of its kind in terms of transparency and openness, complete with manifestos, an election platform, and a vote among all WHO member states. His legitimacy, coupled with focused minds at WHO after the failures of Ebola, means he can do what the global health community has been asking the WHO director-general to do for decades: lead its member states with an ambitious program of effective and measurable work, rather than simply reacting passively to their diverse wishes…

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders

Vaccines and Global Health: The Week in Review has expanded its coverage of new reports, books, research and analysis published independent of the journal channel covered in Journal Watch below. Our interests span immunization and vaccines, as well as global public health, health governance, and associated themes. If you would like to suggest content to be included in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

Women on the move: Migration, care work and health
World Health Organization
2017 : 102 pages
ISBN: 978-92-4-151314-2
PDFs:    Women on the move: Full report
Women on the move: Policy brief
Executive Summary [Excerpt; text bolding from original]
Ageing in late industrial and middle-income economies, combined with rising demographic dependency ratios and female labour force participation, has led to emerging care deficits in many developed and developing countries. Around the world, more women are entering the labour force, thus taking them away from traditional unpaid caring roles.

This report focuses largely on one population group: women migrant care workers who provide home-based personal care. However, many of the issues, and the next steps suggested here, also apply to other migrants and refugees – particularly women and girls – as well as to other socially excluded and marginalized groups engaged in paid and unpaid care work across the world.

Without a doubt, women migrant care workers play an increasingly prominent role in securing and protecting the health status of others and are contributing both to health in the broadest sense and to health systems. Yet relatively little is known about their own health status, the health implications to their families of their out-migration, and the extent of their important contributions to health systems. Around the world, care workers are overwhelmingly female, and many are migrants. This report documents how, despite making a large contribution to global public health, they are exposed to many health risks themselves, while enjoying few labour market and health protections. The report also underscores that paid and unpaid care work is central to the broad health and well-being of individuals, their families and communities, as well as society at large.

The care paradox: global public health and the role of migrant women care workers
Increasingly, immigrant women are being imported into receiving country economies to care, often in informal settings, and are frequently engaged by private households, without full access to social protection and labour rights. Yet this group of migrants provides essential care services and, increasingly, health-care services, thus contributing to health systems and to health and well-being worldwide.

As the leading normative agency on health, the World Health Organization (WHO) calls attention to the paradox that migrant women care workers buttress health systems in countries with shortfalls in health-care provision, while their own rights to health may be eroded and their health-care needs are unfulfilled. Migrant women care workers act as a cushion for states that lack adequate public provision for long-term care, child care and care for the sick.
 
Unmet needs and growing demand for care
Home-based personal care – whether for older persons, children, or those with chronic diseases or disabilities – constitutes an important component of modern health systems. This applies to both high-income countries, where formal health-care institutions and services are struggling to meet the growing demand for such care, as well as to middle- and lower-income countries and regions where home-based care relieves the demand for, and expense of, institutional care. In all societies there is a cultural preference for care “in the family” or for “ageing in place”.

One area in which the care deficit in receiving countries is particularly pronounced is long-term care for older persons. Critical shortages of long-term care workers make quality services  unavailable for large parts of the global population aged 65 years and over. The extent of the unmet need varies worldwide, but in Europe alone the shortage is estimated at around 2.3 million formal long-term care workers.

The policy architecture related to care work, migration and women
The unique status of migrant women care workers as both providers and consumers of health and social care requires that both sending and receiving countries reflect on this paradox and work urgently, and much more collaboratively, to overcome challenges, contradictions, gaps and inconsistencies in international, regional, national and subnational policies, laws and programmes across all relevant sectors. This report proposes the integration of policy actions – and of gender, equity and human rights approaches – to mediate concerns about care deficits and decent and safe work in the care sector as a crucial component of maintaining global and national public health.

Why this report?
WHO initiated this report in response to growing global political interest in population health and development, particularly noting discussions at the 42nd G7 meeting in Japan in May 2016 which called for more attention to migrants and their role in paid and unpaid care work. It is hoped that this report, and its reflection on potential next steps, will foster further debate about approaches to ensure that the global community meets its obligations to leave no one behind in securing long-term equitable and sustainable development. The analysis is also shaped by commitments to the principles of human rights, the Tanahashi Framework on health service coverage and evaluation, the United Nations Migration Governance Framework,i the Framework of priorities and guiding principles for a World Health Assembly Resolution on the health of migrants and refugees, the concept of progressive universalism towards achieving universal health coverage (UHC), and the 2030 Agenda for Sustainable Developmentii with its overarching goal of leaving no one behind…

[See also full-text of Lancet editorial “Caring for migrant health-care workers” in Journal Watch below]

Journal Watch

Journal Watch

   Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

 

Proposed U.S. Funding Cuts Threaten Progress on Antimicrobial Resistance

Annals of Internal Medicine
21 November 2017 Vol: 167, Issue 10
http://annals.org/aim/issue

Ideas and Opinions
Proposed U.S. Funding Cuts Threaten Progress on Antimicrobial Resistance
Antimicrobial resistance (AMR) is an escalating public health crisis that kills patients, threatens national security, and reduces the safety of medical procedures essential to save and enhance lives. Many types of complex medical care can be complicated by serious infections and rely on the availability of safe, effective antimicrobial drugs. In the past 2 years, national and global leaders have united against this threat, making tangible progress. However, budget cuts of a historic magnitude proposed by the Trump administration now threaten to undo this progress, placing patients in grave danger.
The Centers for Disease Control and Prevention (CDC) estimates that at least 2 million persons in the United States acquire antibiotic-resistant infections each year, resulting in at least 23 000 deaths. Antibiotic resistance is estimated to cost our health system more than $20 billion annually (1). Approximately 700 000 deaths are attributable to AMR each year globally. By 2050, a total of 350 million cumulative deaths will likely be attributable to AMR if current trends continue (2), and multidrug-resistant tuberculosis will account for most of these deaths (3).

Unraveling the Epidemiology of Oral Human Papillomavirus Infection

Annals of Internal Medicine
21 November 2017 Vol: 167, Issue 10
http://annals.org/aim/issue

Editorials
Unraveling the Epidemiology of Oral Human Papillomavirus Infection
The burden of oral cancer in the United States has been evolving for at least 2 decades. Gains in head and neck cancer control afforded by a period effect of reduced tobacco exposure have been displaced by competing cohort effects of increasing sexual exposure to human papillomavirus (HPV) infection and subsequent increases in HPV-associated head and neck cancer, particularly oropharyngeal cancer (1). The male predominance of oropharyngeal cancer in the United States is paralleled by a much higher prevalence of oral HPV infection and a stronger relationship between number of sexual partners and oral HPV prevalence in men than women (2). The reason the risk for oral HPV infection differs between men and women remains unclear, particularly because the prevalence of genital HPV infection is similar in both sexes.
Oral Human Papillomavirus Infection: Differences in Prevalence Between Sexes and Concordance With Genital Human Papillomavirus Infection, NHANES 2011 to 2014

Applying systems biology to biomedical research and health care: a précising definition of systems medicine

BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 25 November 2017)

Research article
Applying systems biology to biomedical research and health care: a précising definition of systems medicine
Systems medicine has become a key word in biomedical research. Although it is often referred to as P4-(predictive, preventive, personalized and participatory)-medicine, it still lacks a clear definition and is…
Authors: Sebastian Schleidgen, Sandra Fernau, Henrike Fleischer, Christoph Schickhardt, Ann-Kristin Oßa and Eva C. Winkler
Citation: BMC Health Services Research 2017 17:761
Published on: 21 November 2017

Efficacy and safety of pertussis vaccination for pregnant women – a systematic review of randomised controlled trials and observational studies

BMC Pregnancy and Childbirth
http://www.biomedcentral.com/bmcpregnancychildbirth/content
(Accessed 25 November 2017)

Research article
Efficacy and safety of pertussis vaccination for pregnant women – a systematic review of randomised controlled trials and observational studies
Authors: Marie Furuta, Jacqueline Sin, Edmond S. W. Ng and Kay Wang
Citation: BMC Pregnancy and Childbirth 2017 17:390
Published on: 22 November 2017
Abstract
Background
Worldwide, pertussis remains a major health problem among children. During the recent outbreaks of pertussis, maternal antenatal immunisation was introduced in several industrial countries. This systematic review aimed to synthesize evidence for the efficacy and safety of the pertussis vaccination that was given to pregnant women to protect infants from pertussis infection.
Methods
We searched literature in the Cochrane Central Register of Controlled Trials, Medline, Embase, and OpenGrey between inception of the various databases and 16 May 2016. The search terms included ‘pertussis’, ‘whooping cough’, ‘pertussis vaccine,’ ‘tetanus, diphtheria and pertussis vaccines’ and ‘pregnancy’ and ‘perinatal’.
Results
We included 15 articles in this review, which represented 12 study populations, involving a total of 203,835 mother-infant pairs from the US, the UK, Belgium, Israel, and Vietnam. Of the included studies, there were two randomised controlled trials (RCTs) and the rest were observational studies. Existing evidence suggests that vaccinations administered during 19–37 weeks of gestation are associated with significantly increased antibody levels in the blood of both mothers and their newborns at birth compared to placebo or no vaccination. However, there is a lack of robust evidence to suggest whether these increased antibodies can also reduce the incidence of pertussis (one RCT, n=48, no incidence in either group) and pertussis-related severe complications (one observational study) or mortality (no study) in infants. Meanwhile, there is no evidence of increased risk of serious complications such as stillbirth (e.g. one RCT, n=103, RR=0, meaning no case in the vaccine group), or preterm birth (two RCTs, n=151, RR=0.86, 95%CI: 0.14–5.21) related to administration of the vaccine during pregnancy.
Conclusion
Given that pertussis infection is increasing in many countries and that newborn babies are at greatest risk of developing severe complications from pertussis, maternal vaccination in the later stages of pregnancy should continue to be supported while further research should fill knowledge gaps and strengthen evidence of its efficacy and safety.

BMC Public Health (Accessed 25 November 2017)

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 25 November 2017)

Research article
Estimating disease burden of a potential A(H7N9) pandemic influenza outbreak in the United States
Since spring 2013, periodic emergence of avian influenza A(H7N9) virus in China has heightened the concern for a possible pandemic outbreak among humans, though it is believed that the virus is not yet human-t…
Authors: Walter Silva, Tapas K. Das and Ricardo Izurieta
Citation: BMC Public Health 2017 17:898
Published on: 25 November 2017

Research article
Assessing the impact of the Lebanese National Polio Immunization Campaign using a population-based computational model
After the re-introduction of poliovirus to Syria in 2013, Lebanon was considered at high transmission risk due to its proximity to Syria and the high number of Syrian refugees. However, after a large-scale nat…
Authors: Ali Alawieh, Zahraa Sabra, E. Farris Langley, Abdul Rahman Bizri, Randa Hamadeh and Fadi A. Zaraket
Citation: BMC Public Health 2017 17:902
Published on: 25 November 2017

Clinical Therapeutics November 2017 Volume 39, Issue 11, p2117-2330

Clinical Therapeutics
November 2017 Volume 39, Issue 11, p2117-2330
http://www.clinicaltherapeutics.com/current
TECHNOLOGY IN RESEARCH UPDATE: Social Media and Drug Development

Oncology Update: Gastrointestinal Tract Malignancies
#PatientVoiceMatters: How Social Media Is Bringing Patients and Biopharmaceutical Companies Together to Improve Drug Development
Stella Stergiopoulos
p2170–2172
Published online: October 31, 2017

Original Research
Mapping the Landscape of Patient-centric Activities Within Clinical Research
Mary Jo Lamberti, Josephine Awatin
p2196–2202
Published online: October 9, 2017

Original Research
Mapping the Landscape of Patient-centric Activities Within Clinical Research
Mary Jo Lamberti, Josephine Awatin
p2196–2202
Published online: October 9, 2017

Framing post-pandemic preparedness: Comparing eight European plans

Global Public Health
Volume 13, 2017   Issue 1
http://www.tandfonline.com/toc/rgph20/current

Article
Framing post-pandemic preparedness: Comparing eight European plans
Martin Holmberg & Britta Lundgren
Pages: 99-114
Published online: 07 Mar 2016
ABSTRACT
Framing has previously been studied in the field of pandemic preparedness and global health governance and influenza pandemics have usually been framed in terms of security and evidence-based medicine on a global scale. This paper is based on the pandemic preparedness plans, published after 2009, from eight European countries. We study how pandemic preparedness is framed and how pandemic influenza in general is narrated in the plans. All plans contain references to ‘uncertainty’, ‘pandemic phases’, ‘risk management’, ‘vulnerability’ and ‘surveillance’. These themes were all framed differently in the studied plans. The preparedness plans in the member states diverge in ways that will challenge the ambition of the European Union to make the pandemic preparedness plans interoperable and to co-ordinate the member states during future pandemics.

Map of biomedical research in Cameroon; a documentary review of approved protocols from 1997 to 2012

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 25 November 2017]

Research
Map of biomedical research in Cameroon; a documentary review of approved protocols from 1997 to 2012
Over the last decade, there has been a rapid increase in biomedical research in Cameroon. However, the question of whether these research projects target major health priorities, vulnerable populations and geographic locations at risk remains to be answered. The aim of this paper is to describe the state of biomedical research in Cameroon which is a key determinant that would guide future health care policies and promote equitable access to healthcare.
Ebile Akoh Walter, Ateudjieu Jerome, Djuidje Ngounoue Marceline, Martin Ndinakie Yakum and Watcho Pierre
Published on: 21 November 2017

Development of a framework to improve the utilisation of malaria research for policy development in Malawi

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 25 November 2017]

Research
Development of a framework to improve the utilisation of malaria research for policy development in Malawi
The existing gap between research evidence and public health practice has attributed to the unmet Millennium Development Goals in Africa and consequently, has stimulated the development of frameworks to enhanc…
Chikondi Mwendera, Christiaan de Jager, Herbert Longwe, Charles Hongoro, Kamija Phiri and Clifford M. Mutero
Health Research Policy and Systems 2017 15:97
Published on: 21 November 2017

Special Feature: The Lake Chad Basin: an overlooked crisis?

Humanitarian Exchange Magazine
http://odihpn.org/magazine/the-humanitarian-consequences-of-violence-in-central-america/
Number 70   October 2017
Special Feature: The Lake Chad Basin: an overlooked crisis?
by Humanitarian Practice Network October 2017
The 70th edition of Humanitarian Exchange, co-edited with Joe Read, focuses on the humanitarian crisis in Nigeria and the Lake Chad Basin. The violence perpetrated by Boko Haram and the counter-insurgency campaign in Nigeria, Cameroon, Chad and Niger has created a humanitarian crisis affecting some 17 million people. Some 2.4 million have been displaced, the vast majority of them in north-eastern Nigeria. Many are living in desperate conditions, without access to sufficient food or clean water. The Nigerian government’s focus on defeating Boko Haram militarily, its reluctance to acknowledge the scale and gravity of the humanitarian crisis and the corresponding reticence of humanitarian leaders to challenge that position have combined to undermine the timeliness and effectiveness of the response…
[Reviewed earlier]

Journal of the Pediatric Infectious Diseases Society (JPIDS) Volume 6, Issue 4 December 2017

Journal of the Pediatric Infectious Diseases Society (JPIDS)
Volume 6, Issue 4   December 2017
https://academic.oup.com/jpids/issue

ORIGINAL ARTICLES
Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland
Maria Hemming-Harlo; Timo Vesikari; Matti Uhari; Marjo Renko; Marjo Salminen
Journal of the Pediatric Infectious Diseases Society, Volume 6, Issue 4, 24 November 2017, Pages 317–323, https://doi.org/10.1093/jpids/piw061

Missed Opportunities for Human Papillomavirus Vaccine Initiation in an Insured Adolescent Female Population
Claudia M Espinosa; Gary S Marshall; Charles R Woods; Qianli Ma; Derek Ems
Journal of the Pediatric Infectious Diseases Society, Volume 6, Issue 4, 24 November 2017, Pages 360–365, https://doi.org/10.1093/jpids/pix067
In this cohort of nearly 15000 11-year-old girls with insurance (commercial or Medicaid), the human papillomavirus vaccine was administered at only 1 in 4 well-adolescent visits and approximately one-third of vaccine-related visits, which suggests a substantial number of missed opportunities.

LITERATURE REVIEW
Treatment With Quadrivalent Human Papillomavirus Vaccine for Juvenile-Onset Recurrent Respiratory Papillomatosis: Case Report and Review of the Literature
Tomohiro Katsuta; Yusuke Miyaji; Paul A Offit; Kristen A Feemster
Journal of the Pediatric Infectious Diseases Society, Volume 6, Issue 4, 24 November 2017, Pages 380–385, https://doi.org/10.1093/jpids/pix063
Current evidence to support the efficacy of adjuvant therapies, including therapeutic use of the quadrivalent human papillomavirus vaccine, for juvenile-onset recurrent respiratory papillomatosis is inconsistent. Prophylactic use of the currently available human papillomavirus vaccine in adolescents is the most effective strategy for preventing JoRRP among their children in the future.

Research health needs a dedicated group

Nature 
Volume 551 Number 7681 pp413-528  23 November 2017
http://www.nature.com/nature/current_issue.html

Editorials
Research health needs a dedicated group
A US Research Integrity Advisory Board is long overdue. Such a leadership body would mitigate bad practices and strengthen good research.
Research integrity is often taken to mean misconduct and its prevention. But the integrity of research enfolds much broader dimensions that represent the health — technical, ethical, social and psychological — of research activity. Each of these aspects can be too easily undermined, whether at the level of a university or company department, a research group leader, a research group or an institute. Efforts to preserve integrity need more support.

Many officials in universities and funding agencies increasingly acknowledge how the pressures of academic life undermine the capacity of their researchers to provide due diligence, such as checking the validity of results and mentoring younger scientists. This is compounded by the ever more acute pressures on those younger scientists to deliver high levels of achievement. This combination yields a potentially toxic environment for research, all too ripe for shoddiness or even fraud — and one that an increasing proportion of excellent researchers are voting against with their feet. The costs in wasted research funds are substantial. The United States can take a step forward to help redress the situation, a move that is urgently needed and that can also inspire research leaders and communities in other countries.

Committees at the US National Academies of Sciences, Engineering, and Medicine have twice looked at how to support research integrity (in its more conventional, fraud-busting definition). And both times — in 1992 and 2017 — their recommendations included a proposal for a Research Integrity Advisory Board (RIAB). This year’s report, Fostering Integrity in Research, recommends that the RIAB should be independent of government or other institutions, and funded by subscriptions from stakeholder bodies such as universities and funders.

Such a body would indeed be valuable, and even more so if it were to pursue a broader research-health agenda. It could establish best practices and improve research environments, develop new approaches to incentives and to documenting contributions to research, and develop consensus over standards and penalties for various types of misconduct. It could produce training resources on ethics, and other topics that would help new research-group leaders. It might also encourage funders to introduce conditions of compliance on grants. And it could push for more funds to support efforts by research groups to deliver good research and good mentoring. Funders will jib at the challenge of monitoring compliance, but this important work must start somewhere, and they have remarkable leverage. The RIAB would need a small staff, who would work with others in the research system. It would not take on the role of adjudicating particular cases of misconduct.

One might argue that it is the job of heads of universities and their departments and institutes to develop standards. But the realities of economic and other pressures on institutional leaders divert attention that many would wish to devote to this challenge. Indeed, a functioning RIAB would help to provide university leaders with the clout needed to develop positive changes in culture and practice that are too often resisted by researchers.

The bad news is that, despite the consistent and strong recommendations and the evident need for such a body, there is no discernible gathering of momentum that would help the research community to create one. And the political environment hardly suggests that the federal government will take the lead.

But there are ways forward, nevertheless. By focusing on the broadest agendas, which include support for good research ‘health’ and leadership, alongside measures against bad conduct, the emphasis can be placed where it should be: on a significantly better return in robust research results per dollar of research investment, with researchers better trained to meet today’s demands.

The US National Academies should take the lead. They should propose a working group to develop the agenda and practicalities of an RIAB. The necessary funds should be solicited from federal funders, including the National Institutes of Health and the National Science Foundation, and from private foundations. The group’s deliverables would include a set of priorities, evidence of buy-in from stakeholders, and a timeline for achievements over five- and ten-year timescales. The RIAB is a necessary step towards a culture of research health that can counteract the adverse pressures that so many researchers currently face. We all need it to happen.
doi: 10.1038/d41586-017-07330-5